Literature DB >> 32308488

Comparison of Radiation-Induced Secondary Malignancy Risk Between Sequential and Simultaneous Integrated Boost for the Treatment of Nasopharyngeal Carcinoma: Intensity-Modulated Radiotherapy versus Volumetric-Modulated Arc Therapy.

Emel Haciislamoglu1, Yunus Cinar2, Mehmet Eren2, Emine Canyilmaz1, Fatih Gurcan3, Lasif Serdar4, Adnan Yoney1.   

Abstract

PURPOSE: This study aimed to compare the secondary cancer risk (SCR) between the sequential boost (SEQ) technique and simultaneous integrated boost (SIB) technique in intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with nasopharyngeal carcinoma (NPC) using the concepts of organ equivalent dose (OED) and excess absolute risk (EAR). PATIENTS AND METHODS: IMRT-SEQ, VMAT-SEQ, IMRT-SIB, and VMAT-SIB plans were created with identical objective functions for five patients with early-stage NPC. Three different planning tumor volumes (PTVs; PTV1, PTV2, and PTV3) were delineated for each patient, and the prescribed doses were 50 Gy, 60 Gy, and 70 Gy (2 Gy/fraction), respectively, for the SEQ technique and 52.8 Gy, 59.4 Gy, and 69.3 Gy (33 fractions), respectively, for the SIB technique.
RESULTS: All plans were clinically acceptable. There was no difference in most OED-based SCRs between IMRT and VMAT when the same fractionation scheme was used. Compared with the SEQ technique, the SIB technique in IMRT and VMAT was associated with the lowest OEDs for the oral cavity, pharynx, parotids, and submandibular glands, resulting in SCR reduction. SCR for the parotids was much lower than that for the other assessed organs when the SIB technique was used.
CONCLUSION: Our findings suggest that OED-based SCRs are lower with the SIB technique than with the SEQ technique in IMRT and VMAT in most organs for which SCR was calculated; furthermore, SCR for the parotids is much lower than that for other organs when the SIB technique is used in patients with NPC.
© 2020 Haciislamoglu et al.

Entities:  

Keywords:  excess absolute risk; intensity-modulated radiotherapy; organ equivalent dose; secondary cancer risk; volumetric-modulated arc therapy

Year:  2020        PMID: 32308488      PMCID: PMC7152539          DOI: 10.2147/CMAR.S244901

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  30 in total

1.  Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing.

Authors:  Nesrin Dogan; Stephanie King; Bahman Emami; Najeeb Mohideen; Nena Mirkovic; Leonid B Leybovich; Anil Sethi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

2.  Comparative analysis of SmartArc-based dual arc volumetric-modulated arc radiotherapy (VMAT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Hui-Min Ting; Su-Hua Lo; Yu-Wen Wang; Chiu-Ching Tuan; Fu-Min Fang; Te-Jen Su
Journal:  J Appl Clin Med Phys       Date:  2011-11-15       Impact factor: 2.102

3.  Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.

Authors:  Louise J Murray; Christopher M Thompson; John Lilley; Vivian Cosgrove; Kevin Franks; David Sebag-Montefiore; Ann M Henry
Journal:  Phys Med Biol       Date:  2015-01-15       Impact factor: 3.609

4.  Intensity-modulated radiation therapy in head-and-neck cancer, first report in Thailand.

Authors:  Chawalit Lertbutsayanukul; Chonlakiet Khorprasert; Kanjana Shotelersuk; Chotika Jumpangern; Taweap Sanghangthum; Sornjarod Oonsiri; Isra Israngkul Na Ayuthaya; Sivalee Suriyapee; Winai Wadwongtham; Siripornchai Supanakorn; Virachai Kerekanjanarong; Prayuth Rojpornpradit
Journal:  J Med Assoc Thai       Date:  2006-12

5.  Radiation-induced sarcoma of head and neck: 50 years of experience at a single institution in an endemic area of nasopharyngeal carcinoma in China.

Authors:  Zhengbo Wei; Ying Xie; Jian Xu; Yuan Luo; Falong Chen; Yunli Yang; Qifang Huang; Anzhou Tang; Guangwu Huang
Journal:  Med Oncol       Date:  2011-01-23       Impact factor: 3.064

6.  Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy.

Authors:  David Palma; Emily Vollans; Kerry James; Sandy Nakano; Vitali Moiseenko; Richard Shaffer; Michael McKenzie; James Morris; Karl Otto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

8.  Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.

Authors:  Michael K M Kam; Sing-Fai Leung; Benny Zee; Ricky M C Chau; Joyce J S Suen; Frankie Mo; Maria Lai; Rosalie Ho; Kin-yin Cheung; Brian K H Yu; Samuel K W Chiu; Peter H K Choi; Peter M L Teo; Wing-hong Kwan; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

9.  Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma.

Authors:  Anussara Songthong; Chakkapong Chakkabat; Danita Kannarunimit; Chawalit Lertbutsayanukul
Journal:  Radiol Oncol       Date:  2015-03-25       Impact factor: 2.991

10.  Comparison of long-term survival and toxicity of simultaneous integrated boost vs conventional fractionation with intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma.

Authors:  Hengmin Tao; Yumei Wei; Wei Huang; Xiujuan Gai; Baosheng Li
Journal:  Onco Targets Ther       Date:  2016-03-31       Impact factor: 4.147

View more
  1 in total

1.  Development of clinical application program for radiotherapy induced cancer risk calculation using Monte Carlo engine in volumetric-modulated arc therapy.

Authors:  Dong-Jin Kang; Young-Joo Shin; Seonghoon Jeong; Jae-Yong Jung; Hakjae Lee; Boram Lee
Journal:  Radiat Oncol       Date:  2021-06-12       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.